Roche and Genentech have filed an sBLA for Avastin in the U.S. for the treatment of non-squamous, non-small cell lung cancer (NSCLC). The sBLA has been submitted for use of Avastin in combination with a platinum-based chemotherapy for previously untreated patients suffering from advanced NSCLC, which accounts for 87% of all lung cancers cases. The sBLA submission is based on Genentech’s results of the E4599 trial that enrolled 878 patients with locally advanced, metastatic or recurrent...